Articles On Capitol Health (ASX:CAJ)

Title Source Codes Date
Markets slide as new data raises renewed inflation fears

  US markets kicked off the post Easter week by giving up ground on what was a winning month for March and a strong first quarter. New inflation data raised concerns that the Fed may struggle to hit its target of three rate cuts by the end...

ShareCafe CAJ 2 weeks ago
Rudi’s Comprehensive February 2024 Review

A compilation of stories relating to the February 2024 corporate reporting season in Australia, including FNArena’s final balance for the season. Content (in chronological order of publication): -Healthcare, REITs, Uranium & Banks-Rudi...

FNArena CAJ 3 weeks ago
Capitol Health’s Higher Margin Outlook

Capitol Health’s first half results exceeded brokers’ expectations with higher margins thanks largely to good cost control. -Brokers raise targets following Capitol Health’s first half results-The earnings margin increased by 200bps due to...

FNArena CAJ 1 month ago
Australian Broker Call *Extra* Edition – Mar 12, 2024

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

FNArena CAJ 1 month ago
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Stockhead CAJ 1 month ago
Nasdaq pulls back after steep declines from big tech names

  US stocks fell for a second session Tuesday, as steep declines in major tech names such as Apple dragged the broader market further from the record highs recently reached. The Nasdaq Composite pulled back by 1.65 per cent to 15,939.59 as...

ShareCafe CAJ 1 month ago
FNArena Corporate Results Monitor – 01-03-2024

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AGI)) - Ainsworth Game Technology ((ART)) - Airtasker ((ALX)) - Atlas Arteria ((AFG)) - Australian Finance Group ((CAJ)) - Capitol Health ((CLU)) - Cluey ((DOC)) - Docto...

FNArena CAJ 1 month ago
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Stockhead CAJ 1 month ago
ESG Focus: The Little Big Things – 30-11-2023

FNArena's dedicated ESG Focus news section zooms in on matters Environmental, Social & Governance (ESG) that are increasingly guiding investors preferences and decisions globally. For more news updates, past and future: https://www.fnar...

FNArena CAJ 4 months ago
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Stockhead CAJ 5 months ago
CAJ ASX | Capitol Health Ltd | Market Insights, News & Analysis | Livewire

Livewire CAJ 5 months ago
US stocks slide following comments from Fed Chair Jay Powell

Stocks slid on Thursday as Wall Street parsed commentary from Federal Reserve Chair Jerome Powell while monitoring a key milestone for a closely followed bond yield. Powell noted that inflation was still too high and would likely require lo...

ShareCafe CAJ 5 months ago
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Stockhead CAJ 5 months ago
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Stockhead CAJ 6 months ago
Stocks dip as Fed holds rates steady, hints at future hike

  Stocks retreated on Wednesday after the Federal Reserve said it would leave interest rates unchanged but indicated another hike on the horizon. The three major indexes closed at session lows. The S&P 500 dropped 0.94 per cent to 4,402...

ShareCafe CAJ 6 months ago
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Stockhead CAJ 7 months ago
Rudi’s View: Outlook Negative, With Plenty Of Silver Linings

In this week's Weekly Insights:-Outlook Negative, With Plenty Of Silver Linings-Conviction Calls & Best IdeasBy Rudi Filapek-Vandyck, EditorOne of the stand-out features of the August results season has been the resilience of household ...

FNArena CAJ 7 months ago
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Stockhead CAJ 7 months ago
Australian Broker Call *Extra* Edition – Aug 31, 2023

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

FNArena CAJ 7 months ago
Check Up: Australian biotech sector continues to be a magnet for US investors

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Stockhead CAJ 7 months ago
FNArena Corporate Results Monitor – 25-08-2023

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AX1)) - Accent Group ((A1M)) - AIC Mines ((AIZ)) - Air New Zealand ((ALC)) - Alcidion Group ((ALK)) - Alkane Resources ((APA)) - APA Group ((A1N)) - ARN Media ((AIA)) -...

FNArena CAJ 7 months ago
Cochlear Ltd (ASX:COH) share price pops: our Cochlear thesis

The Cochlear Limited (ASX: COH) share price bounced dramatically higher this week following a bumper report. But is the Cochlear share price looking a little expensive? Stock Doctor’s Daniel Ortisi weighs in. Hearing solutions provider Coch...

Rask Media CAJ 8 months ago
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Stockhead CAJ 8 months ago
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Stockhead CAJ 8 months ago
9 ASX shares Goldman Sachs tips to positively surprise this earnings season

Earnings season has now kicked off and countless ASX shares are getting ready to hand in their report cards. Goldman Sachs has been running the rule over the market and has picked out a number of ASX shares as having potential for positive...

Motley Fool CAJ 8 months ago
‘Best positioned’: 2 ASX mining shares about to explode

There is no getting around that smaller ASX mining shares can be risky. That’s because junior miners are often involved in exploration and that tends to have a binary outcome — you either find the mineral or you don’t. But if you can manag...

Motley Fool CAJ 8 months ago
Top brokers name 3 ASX shares to buy today

Many of Australia’s top brokers have been busy adjusting their financial models again, leading to the release of a number of broker notes this week. Three ASX shares brokers have named as buys this week are listed below. Here’s why the...

Motley Fool CAJ 9 months ago
Morgans says these are the best ASX growth shares to buy in July

If you’re looking for ASX growth shares to buy, then look no further. That’s because Morgans has recently named some among its best ideas for the month of July. Two that make the cut are listed below. Here’s why it is very bullis...

Motley Fool CAJ 9 months ago
The disappointing ASX sector now ready for a MASSIVE winter revival

For more than a year now, experts have been saying ASX healthcare shares are the place to park your money. The reasoning is that health is a type of spending that consumers are reluctant to cut back even in times of economic stress.  But l...

Motley Fool CAJ 9 months ago
3 former ASX market darlings now trading at 52-week lows. Are they cheap buys?

Unfortunately for investors, there’s no guarantee that today’s market darlings will remain in favour with investors in the future. When companies go through difficult periods, many investors will sell off their holdings and move onto s...

Motley Fool CAJ 9 months ago
Australian Broker Call *Extra* Edition – Jun 30, 2023

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

FNArena CAJ 9 months ago
2 ‘pleasing’ ASX 200 tech shares to get your hands on right now

While US and Japanese stocks have shot ahead in 2023, the S&P/ASX 200 Index (ASX: XJO) has been left behind. Many experts attribute this to the relatively small presence of the technology sector in the Australian market. The ASX 200 i...

Motley Fool CAJ 9 months ago
Are beaten-up Bega shares a bargain buy?

Bega Cheese Ltd (ASX: BGA) shares have continued their decline on Thursday. In morning trade, the diversified food company’s shares have dropped 3% to a new decade-low of $3.02. This means they are now down over 21% since the start of th...

Motley Fool CAJ 9 months ago
Guess which ASX 200 stock has plunged to a 10-year low

The Bega Cheese Ltd (ASX: BGA) share price was in a world of pain on Wednesday, cascading to its lowest level in almost a decade. Bega’s bitter performance stood out like a sore thumb against a backdrop of the S&P/ASX 200 Index (ASX: X...

Motley Fool CAJ 9 months ago
Why Bega Cheese, Capitol Health, Centaurus Metals, and Seek shares are falling

The S&P/ASX 200 Index (ASX: XJO) is on form again and on course to record a strong gain. In afternoon trade, the benchmark index is up 1.2% to 7,202.1 points. Four ASX shares that have failed to follow the market higher today are lis...

Motley Fool CAJ 9 months ago
ASX Health Stocks: Invex granted orphan drug designation in Europe; Resonance has a new CEO

Invex granted orphan drug designation in Europe Resonance Health has a new CEO EBR to raise $35m as it eyes market launch   Invex Therapeutics (ASX:IXC) announced the granting of orphan drug designation (ODD) from the European Medicines A...

Stockhead CAJ 9 months ago
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Stockhead CAJ 9 months ago
MoneyTalks: Why Goldman recommends these two ASX stocks in the booming diagnostic imaging space

Goldman has Buy recommendations for health imaging stocks Capitol Health and Integral Diagnostics Capitol Health’s earnings multiple is cheap, says Goldman Integral is currently Goldman’s cheapest stock across its coverage   Goldman Sachs...

Stockhead CAJ 10 months ago
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Stockhead CAJ 10 months ago
Goldman Sachs has just slapped buy ratings on these ASX healthcare shares

If you’re wanting exposure to the healthcare sector, then it could be worth listening to what Goldman Sachs is recommending at this side of the market. It has been looking at the services side of the sector and has picked out two ASX hea...

Motley Fool CAJ 10 months ago
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Stockhead CAJ 10 months ago
‘Highly sought-after’: 3 ASX healthcare shares ready to roar again

In turbulent times such as now, ASX healthcare shares have typically been in favour. After all, even when high inflation or rising interest rates eat into spending power, consumers still want to take care of their physical and mental well-...

Motley Fool CAJ 10 months ago
Check Up: Here’s how diabetes drugs can help you get off the beers and lose weight

Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week   Earlier this week, Pfizer surprised the market by say...

Stockhead CAJ 10 months ago
Check Up Budget Edition: Which ASX healthcare stocks will reap benefits from the Budget?

The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit   Medicare, telehealth and mental...

Stockhead CAJ 11 months ago
79% upside: The ‘frustrating’ ASX share waiting to take off

The efficient market hypothesis says share prices always reflect all available information about the businesses. However, veteran ASX investors would know that in reality that’s not necessarily true. Sometimes the market just fails to full...

Motley Fool CAJ 11 months ago
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Stockhead CAJ 11 months ago
A note to young investors part 2: How to invest in quality growth stocks

In part one of this note to young investors, I set out the reasons why I think young investors should steer clear of index funds and instead invest in high-quality, growing companies. So, the question is: how to find and invest in these com...

Montgomery CAJ 11 months ago
2 ASX shares to buy that no one talks about

You want your portfolio to perform better than the market, right? If not, then you might as well just buy passive ETFs and be done with it. The whole point of owning a basket of company-specific stocks is because you want better returns t...

Motley Fool CAJ 1 year ago
S&P500 rises on hopes that the worst of bank crisis is over

ShareCafeS&P500 rises on hopes that the worst of bank crisis is over                    The S&P 500 rose Thursday, as investors bet the worst of the regional bank crisis has passed. Weekly jobless claims increased by 7,000 to...

ShareCafe CAJ 1 year ago
The Overnight Report: Not With A Bang

World Overnight SPI Overnight 7177.00 – 21.00 – 0.29% S&P ASX 200 7258.40 + 33.60 0.47% S&P500 3970.15 – 12.09 – 0.30% Nasdaq Comp 11455.54 – 11.44 – 0.10% DJIA 32656.70 – 232.39 – 0.71% S&P500 VIX 20.70 – 0.25 – 1...

FNArena CAJ 1 year ago